Recombinant factor VIIa in patients with platelet function disorders or thrombocytopenia;Rekombinanter faktor VIIa bei patienten mit plättchenfunktionsstö rungen oder thrombozytopenien

Hamostaseologie

Volumn 27, Issue 4, 2007, Pages 251-262

  Zotz, Rainer B ^a   Scharf, R E ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Bleeding; Haemostasis; Recombinant factor VIIa; Thrombocytopathy; Thrombocytopenia

Indexed keywords

ABCIXIMAB; DESMOPRESSIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BERNARD SOULIER DISEASE; BLEEDING; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; GLANZMANN DISEASE; HOMEOSTASIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 35348941271     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617090     Document Type: Conference Paper

References (96)

1. Almeida AM, Khair K, Hann I et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121:477-481.
2. Ameri A, Stolte S. Correlation of activated clotting time (ACT) with rFVIIa infusion and clinical efficacy in a patient with Glanzmann thrombasthenia and platelet alloantibodies. Thromb Haemost 2002; 87: 1084.
3. Ancliff P, Liesner R, Khair K et al. The use of recombinant factor VIIa in a patient with severe Glanzmann's thrombasthenia to facilitate insertion of a Port-a-Cath. Blood Coagul Fibrinolysis 1999; 10: 447-448.
4. Altman R, Scazziota A, De Lourdes Herrera M et al. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006; 4: 2022-2027.
5. Barnes C, Blanchette V, Canning P et al. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 2005; 15: 145-150.
6. Baxter MS, Schroeder WS, Cheng Y et al. Diminished response to recombinant factor VIIa in a patient with idiopathic thrombocytopenic purpura. Ann Pharmacother 2006; 40: 2053-2058.
7. Bay A, Oner AF. Glanzmann thrombasthenia successfully operated for nasal deformation with recombinant factor VIIA. Indian Pediatr 2006; 43: 1094.
8. Bell JA, Savidge GF. Glanzmann's thrombasthenia proposed optimal management during surgery and delivery. Clin Appl Thromb Hemost 2003; 9: 167-170.
9. Brenner B, Hoffman R, Balashov D et al. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII. Clin Appl Thromb Hemost 2005; 11: 401-410.
10. Busani S, Marietta M, Pasetto A et al. Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage. Thromb Haemost 2005; 93: 381-382.
11. Caglar K, Cetinkaya A, Aytac S et al. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol 2003; 20: 435-438.
12. Chuansumrit A, Sangkapreecha C, Hathirat P. Successful epistaxis control in a patient with Glanzmann Thrombasthenia by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost 1999; 82: 1778.
13. Chuansumrit A, Suwannuraks M, Sri-Udomporn N et al. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis 2003; 14: 187-190.
14. Cervera JS, Mena-Duran AV, Piqueras CS. The use of recombinant factor VIIa in a patient with essential thrombocythaemia with uncontrolled surgical bleeding. Thromb Haemost 2005; 93: 383-384.
15. Conesa V, Navarro-Ruiz A, Borras-Blasco J et al. Recombinant factor VIIa is an effective therapy for abdominal surgery and severe thrombocytopenia: a case report. Int J Hematol 2005; 81: 75-76.
16. Coppola A, Simone CD, Palmieri NM et al. Recombinant activated factor VII for hemostatic cover of orthopaedic interventions in a girl with thrombocytopenia with absent radii syndrome. Blood Coagul Fibrinolysis 2007; 18: 199-201.
17. Coppola A, Tufano A, Cimino E et al. Recombinant factor VIIa in a patient with Glanzmann's thrombasthenia undergoing gynaecological surgery: open issue in light of successful treatment. Thromb Haemost 2004; 92: 1450-1452.
18. Culic S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003; 120: 909-910.
19. Culligan DJ, Salamat A, Tait J et al. Use of recombinant factor VIIa in life-threatening bleeding following autologous peripheral blood stem cell transplantation complicated by platelet refractoriness. Bone Marrow Transplantation 2003; 31: 1183-1184.
20. D'Oiron R, Ménart C, Trzeciak MC et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-647.
21. Dargaud Y, Bordet JC, Trzeciak MC et al. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 2006; 91: 17-20.
22. De Fabritiis P, Dentamaro T, Picardi A et al. Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. Haematologica 2004; 89: 243-245.
23. Del Pozo Pozo AI, Jimenez-Yuste V, Villar A et al. Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagul Fibrinolysis. 2002; 13: 551-553.
24. Devecioglu O, Unuvar A, Anak S et al. Pyelithotomy in a patient with Glanzmann Thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions. Turkish J Ped 2003; 45: 64-66.
25. Dominguez TE, Mitchell M, Friess SH et al. Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2005; 6: 348-351.
26. Dempfle CE, Gulba D, Kirchmaier CM et al. Klinische Bewertung potentieller Einsatzbereiche von rekombinantem Faktor VIIa bei internistischen und pädiatrischen Erkrankungen. Med Klin 2007; 102: 70-81.
27. Eller P, Pechlaner C, Wiedermann CJ. Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation- related gastrointestinal bleeding. Thromb J 2006; 4: 1477-1495.
28. Franchini M. The use of recombinant activated factor VII in life-threatening postpartum hemorrhage. Transfusion Alternatives in Transfusion Medicine 2007; 9: 1-7.
29. Gabriel DA, Li X, Monroe DM et al. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost 2004; 2: 1816-1822.
30. Galan AM, Tonda R, Pino M et al. Increased local procoagulant action: a mechanism contributing to the favourable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion 2003; 43: 885-892.
31. George JN, Colman RW. Overview of platelet structure and function. In: Colman et al. (eds). Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott Williams and Wilkins, 2006: 437-442.
32. Gerhardt A, Scharf RE, Zotz RB. The use of recombinant factor VIIa (NovoSeven®) in a patient with Bernard Soulier syndrome and dental extraction. Blood 2006; 108: 67B.
33. Gerotziafas GT, Chakroun T, Depasse F et al. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004; 91: 977-985.
34. Gerotziafas GT, Zervas C, Gavrielidis G et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 2002; 69: 219-222.
35. Gunaydin B, Ozkose Z, Pezek S. Recombinant activated factor VII and epsilon aminocaproic acid treatment of a patient with Glanzmann's thrombasthenia for nasal polipectomy. J Anesth 2007; 21: 106-107.
36. Heuer L, Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinolysis 2005; 16: 287-290.
37. Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975-978.
38. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
39. Hoffman R, Eliakim R, Zuckerman T et al. Successful use of recombinant activated factor VII in controlling upper gastrointestinal bleeding in a patient with relapsed acute myeloid leukaemia. J Thromb Haemost 2003; 1: 606-608.
40. Inagaki M, Mori T, Tsunematsu Y et al. Use of recombinant activated factor VII to control bleeding in a young child with qualitative platelet disorder: a case report. Blood Coagul Fibrinolysis 2006; 17: 317-322.
41. Kale A, Bayhan G, Yalinkaya A et al. The use of recombinant factor VIIa in a Primigravida with Glanzmann's thrombasthenia during delivery. J Perinat Med 2004; 32: 456-458.
42. Kaleelrahman M, Minford A, Parapia LA. Use of recombinant factor VIIa in inherited platelet disorders. Br J Haematol 2004; 125: 95-96.
43. Kjalke M, Johannessen M, Hedner U. Effect of recombinant factor VIIa (NovoSeven®) on thrombocytopenia-like conditions in vitro. Semin Hematol 2001; 38 (suppl 12): 15-20.
44. Kjalke M, Kjellev S, Rojkjaer R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost 2007; 5: 774-780.
45. Kristensen J, Killander A, Hippe E et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996; 26 (Suppl1): 159-164.
46. Kurekci AE, Atay AA, Okutan V et al. Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. Blood Coagul Fibrinolysis 2005; 16: 145-147.
47. Langendonck L, Appel IM, Modification of biological parameters after treatment with recombinant factor VIIa in a patient with thrombocytopathy due to storage pool disease. Pediatr Blood Cancer 2005; 44: 676-678.
48. Lisman T, Moschatsis S, Adelmeijer J et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101: 1864-1870.
49. Lisman T, Adelmeijer J, Heijnen HF et al. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103: 1720-1727.
50. Lisman T, Adelmeijer J, Cauwenberghs S et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005; 3: 742-751.
51. Loertzer H, Soukup J, Fornara P. Recombinant factor VIIa reduces bleeding risk in patients on platelet aggregation inhibitors immediately prior to renal transplantation - a retrospective analysis. Urol Int 2007; 78: 135-139.
52. Lombardo VT, Sottilotta G. Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann's thrombasthenia. Clin Appl Thromb Hemost 2006; 12: 115-116.
53. Lopez-Vilchez I, Escolar G, Diaz-Ricart M et al. Tissue factor-enriched vesicles are taken up by platelets and induce platelet aggregation in the presence of factor VIIa. Thromb Haemost 2007; 97: 202-211.
54. Meijer K, Sieders E, Sloof MJH et al. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII. Thromb Haemost 1998; 80: 204-205.
55. Millar CG, Stringer MD, Sugarman I et al. The use of recombinant factor VIIa for bleeding in paediatric practice. Haemophilia 2005; 11: 171-174.
56. Moisescu E, Ardelean L, Simion I et al. Recombinant factor VIIa treatment of bleeding associated with acute renal failure. Blood Coagul Fibrinolysis 2000; 11: 575-577.
57. Monroe DM, Hoffman M, Allen GA et al. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost 2000; 26: 373-377.
58. Monte S, Lyons G. Peripartum management of a patient with Glanzmann's thrombasthenia using Thrombelastograph®. Br J Anaesthesia 2001; 87: 734-738.
59. Ng HJ, Koh LP, Lee LH. Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 2003; 82: 257-258.
60. Nieswandt B, Watson SP. Platelet-collagen interaction: is GP VI the central receptor? Blood 2003; 102: 449-461.
61. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinatology 2002; 22: 672-674.
62. Osborne W, Bhandari S, Tait RC et al. Immediate haemostasis with recombinant factor VIIa for haemorrhage following Hickman line insertion in acute myeloid leukaemia. Clin Lab Haematol 2004; 26: 229-231.
63. Ozelo MC, Svirin P, Larina L. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol 2005; 84: 816-822.
64. Pastores SM, Papadopoulos E, Voigt L et al. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. Chest 2003; 124: 2400-2403.
65. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier Syndrome and recurrent nose-bleeds with recombinant factor VIIa. Thromb Haemost 1998; 80: 352.
66. nd, Broder J, Kouides PA. Near-fatal uterine hemorrhage during induction chemotherapy for acute myeloid leukemia: a case report of bilateral uterine artery embolization. Am J Hematol 2004; 77: 151-155.
67. Pihusch M, Bacigalupo A, Szer J et al. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005; 3: 1935-1944.
68. Poon M-C, Demers C, Jobin F et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann Thrombasthenia. Blood 1999; 94: 3951-3953.
69. Poon MC, D'Oiron R, von Depka M et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2: 1096-1103.
70. Poon MC, Zotz R, Di Minno G et al. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 2006; 43 (Suppl 1): S33-S36.
71. Revesz T, Arets B, Bierings M et al. Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost 1998; 80: 355.
72. Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999; 94: 172-178.
73. Scharf RE. Arterielle Thrombose. In: Ostendorf PC, Scharf RE, Aumiller J et al. Thrombose Hämatologie-Onkologie. Ostendorf PC, Seeber S (Hrsg). München: Urban-Schwarzenberg 1997; 389-408.
74. Scharf RE, Clemetson KJ. Bernard-Soulier-Syndrom. In: Müller-Berghaus G, Pötzsch B (Hrsg). Hämostaseologie. Molekulare und zelluläre Mechanismen, Pathophysiologie und Klinik. Heidelberg: Springer 1998; 53-56.
75. Scharf RE: Molecular basis and clinical aspects of hereditary megakaryocyte and platelet membrane glycoprotein disorders. Hämostaseologie 1996; 16: 114-138.
76. Savani BN, Dunbar CE, Rick ME. Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol 2006; 81: 218-219.
77. Stepinska J, Banaszewski M, Konopka A et al. Activated recombinant factor VII in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Thromb Haemost 2002; 87: 355-356.
78. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75: 971-982.
79. Tonda R, Galan AM, Mazzara R et al. Platelet membrane fragments enhance the procoagulant effect of recombinant factor VIIa in studies with circulating human blood under conditions of experimental thrombocytopenia. Semin Hematol 2004; 41 (Suppl 1): 157-162.
80. Uzunlar HI, Eroglu A, Senel AC et al. A patient with Glanzmann's thrombasthenia for emergent abdominal surgery. Anesth Analg 2004; 99: 1258-1260.
81. Valentino LA. Use of rFVIIa in 4 children with Glanzmann thrombasthenia. J Pediatr Hematol Oncol 2006; 28: 653-658.
82. Van Buuren HR, Wilenga JJ. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia. Dig Dis Sci 2002; 47: 2134-2136.
83. Vidarsson B, Onundarson P. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000; 83: 634-635.
84. Virchis A, Hughes C, Berney S. Severe gastrointestinal haemorrhage responding to recombinant factor VIIa in a Jehovah's Witness with refractory immune thrombocytopenia. Hematol J 2004; 5: 281-282.
85. Von Heymann C, Schoenfeld H, Sander M et al. Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates? Heart Surg Forum 2005; 8: E39-E41.
86. Von Heymann C, Spies C, Grubitzsch H et al. Blutungen nach herzchirurgischen Operationen. Die Rolle des rekombinanten Faktors VIIa. Hämostaseologie 2006; 26 (Suppl 1): S77-S87.
87. Waddington DR McAuley FT, Hanley JP et al. The use of recombinant factor viia in a Jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage. Br J Haematol 2002; 119: 286-288.
88. Walsh PN. Role of platelets in blood coagulation. In: Colman R. W. et al. (eds). Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia: Lippincott Williams and Wilkins, 2006: 605-616.
89. Westrup D, Bassus S, Kirchmaier C et al. Ultrastructure of a platelet clot from a thrombasthenia patient with no GPIIb/IIIa receptors and the influence of rFVIIa substitution. Platelets 2002; 13: 487-491.
90. White GC. Congenital and acquired platelet disorders: current dilemmas and treatment strategies. Semin Hematol 2006; 43 (Suppl 1): S37-S41.
91. Wiesenack C, Arlt M, Liebold A et al. Successful use of one dose of recombinant factor VIIa to control severe bleeding after emergency aortic arch replacement in deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg 2004; 128: 941-943.
92. Wilbourn B, Harrison P, Mackie IJ et al. Activation of platelets in whole blood by recombinant factor VIIa by a thrombin-dependent mechanism. Br J Haematol 2003; 122: 651-661.
93. Wrobel G, Dobaczewski G, Patkowski D et al. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer 2006; 47 (Suppl): 729-730.
94. Yilmaz BT, Alioglu B, Ozyurek E et al. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol 2005; 26: 843-845.
95. Zulfikar B, Kayran SM. Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven). Blood Coagul Fibrinolysis 2004; 15: 261-263.
96. Hacihanefioglu A, Tarkun P, Gonullu E. Use of recombinant factor VIIa in the management and prophylaxis of bleeding episodes in two patients with Bernard-Soulier-syndrome. Thromb Res 2007; 120: 455-457.